Trade BRVE stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Braveheart Bio, Inc. (BRVE) is trading at US$21.44, down 0.19% today as of Oct 23, 16:00 EDT. The company has a market capitalisation of US$1.95B. Over the past 52 weeks, BRVE has traded between US$17.00 and US$32.00. On Syfe you can trade BRVE with $0 commission and add it to your watchlist.
| Previous close | US$21.48 |
|---|---|
| Market cap | US$1.95B |
| 52-week range | US$17.00 – US$32.00 |
| Volume | 118.84K |
| Exchange | US |
Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Year: 2026
Braveheart Bio Q2 Net Loss Widens
Sep 8, 8:29 PM · MT Newswires
--Earnings Flash (BRVE) Braveheart Bio Posts Q2 Loss $2.51 per Share
Sep 8, 8:13 PM · MT Newswires
--Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target
Aug 31, 10:32 AM · MT Newswires
--TD Cowen Initiates Braveheart Bio at Buy
Aug 31, 10:08 AM · MT Newswires
--Jefferies Initiates Braveheart Bio at Buy With $48 Price Target
Aug 31, 9:58 AM · MT Newswires
Braveheart Bio, Inc. (BRVE) stock is trading at US$21.44, -0.19% from the previous close of US$21.48.
The market cap for Braveheart Bio, Inc. (BRVE) stock is approximately US$1.95B.
The 52-week high for Braveheart Bio, Inc. (BRVE) stock is US$32.00.
The 52-week low for Braveheart Bio, Inc. (BRVE) stock is US$17.00.
Braveheart Bio, Inc. (BRVE) does not currently pay a dividend.
Stay on top of BRVE
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
